title: Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.
abstract: Unconjugated hyperbilirubinemia resulting from therapy with atazanavir is physiologically related to hyperbilirubinemia in Gilbert's syndrome (GS). In patients with GS, changes in diet have a significant impact on bilirubinemia. Our aim was to investigate whether changes in diet affect the level of serum bilirubin in patients receiving atazanavir. Thirty patients on stable therapy with ritonavir-boosted atazanavir without evidence of GS were enrolled. Hemolysis and chronic hepatitis were excluded. After a baseline period of normal intake of calories, the patients were randomized to follow a 24-h 400-calorie diet (fasting), then a 48-h period of normal calorie intake and, afterward, a 24-h period of a high-calorie diet, or the same interventions in inverse order. Serum bilirubin concentrations were measured before and after each intervention. A high adherence to the recommended diet was observed. The mean unconjugated bilirubin concentration before the high-calorie diet was 2.79±1.53 mg/dl and after such intervention it was 2.70±1.40 mg/dl. The mean difference between preintervention and postintervention was -0.08±0.69 mg/dl (p=NS). The mean unconjugated bilirubin concentration before the fasting diet was 2.31±1.23 mg/dl and it was 3.84±1.90 mg/dl after. The mean difference between prefasting and postfasting was 1.53±1.17 mg/dl (p=0.001). According to these results, short periods of fasting seem to increase the unconjugated bilirubin concentration in patients on atazanavir. A high-calorie diet did not have any impact in bilirubin probably because most patients follow similar diets in their everyday life.
authors.affiliation: Fundación del Centro de Estudios Infectológicos, FUNCEI, Buenos Aires, Argentina. glopardo@intramed.net
authors.forename: Gustavo
authors.initials: G
authors.lastname: Lopardo
authors.forename: Emiliano
authors.initials: E
authors.lastname: Bissio
authors.forename: Lidia
authors.initials: L
authors.lastname: Espinola
authors.forename: Paula
authors.initials: P
authors.lastname: Gallego
authors.forename: Marcela
authors.initials: M
authors.lastname: Stambullian
authors.forename: Adrián
authors.initials: A
authors.lastname: Gadano
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D001663:Bilirubin / Q000097:blood*; D005215:Fasting; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced* / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D044967:Serum / Q000737:chemistry
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D001663:Bilirubin